title: [Surveillance of acute flaccid paralysis in Belarus].
abstract: The ten-years experience of acute flaccid paralysis (AFP) surveillance in Belarus has been summarized. Among 456 AFP cases reported from 1996 to 2005, 11 were classified as vaccine-associated paralytic poliomyelitis (VAPP), 445--as non-polio AFP. The risk of VAPP for the period 1996-2001 was 1 case per 745,000 used doses of oral poliovaccine (OPV). For the recipients of OPV the risk was 1 case per 911,700 doses and for the first-dose recipients--1 case per 96,000 doses. The high incidence of VAPP was a reason for implementation of sequential polio vaccination schedule in 2000. Guillain-Barre syndrome dominated among non-polio AFP (39.3% of cases); more rare were traumatic neuritis (27.9% of cases), transient monoparalysis (12.1%), myelitis (7.6%). Non-polio AFP differed from VAPP by following epidemiological and virological characteristics: predominance of previously repeatedly vaccinated against poliomyelitis; development of paralysis in long-term period after vaccination; isolation of non-polio viruses belonged to three serotypes of Coxsackie B viruses (B1, B4, B6) and six serotypes of Echo viruses (6, 7, 11, 14, 24, 25) in 8.1% of cases; absence of typical for polio residual paralyses in patients who excreted vaccine polioviruses.
authors.forename: E O
authors.initials: EO
authors.lastname: Samoĭlovich
authors.forename: M A
authors.initials: MA
authors.lastname: Ermolovich
authors.forename: I F
authors.initials: IF
authors.lastname: Kotova
authors.forename: E Iu
authors.initials: EIu
authors.lastname: Svirchevskaia
authors.forename: V P
authors.initials: VP
authors.lastname: Shimanovich
authors.forename: A K
authors.initials: AK
authors.lastname: Kozhemiakin
authors.forename: I I
authors.initials: II
authors.lastname: Protas
authors.forename: E V
authors.initials: EV
authors.lastname: Fel'dman
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D000914:Antibodies, Viral / Q000097:blood; D016022:Case-Control Studies; D003384:Coxsackievirus Infections / Q000175:diagnosis / Q000517:prevention & control / Q000821:virology; D029822:Enterovirus B, Human / Q000145:classification / Q000302:isolation & purification; D016679:Genome, Viral; D020275:Guillain-Barre Syndrome / Q000517:prevention & control; D006801:Humans; D015994:Incidence; D009123:Muscle Hypotonia / Q000209:etiology / Q000517:prevention & control*; D009187:Myelitis / Q000517:prevention & control; D009443:Neuritis / Q000517:prevention & control; D010243:Paralysis / Q000209:etiology / Q000517:prevention & control*; D011051:Poliomyelitis / Q000175:diagnosis / Q000276:immunology / Q000517:prevention & control; D017955:Poliovirus / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage; D011055:Poliovirus Vaccine, Oral / Q000008:administration & dosage / Q000009:adverse effects; D002094:Republic of Belarus / Q000453:epidemiology; D012307:Risk Factors; D018571:Sentinel Surveillance; D013045:Species Specificity; D014611:Vaccination / Q000009:adverse effects
chemical_list: D000914:Antibodies, Viral; D011054:Poliovirus Vaccine, Inactivated; D011055:Poliovirus Vaccine, Oral